Evidence map›Paper›PMID 32495455›Full record

Trial reportCancer science2020

Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer.

Uhi Toh, Sayaka Sakurai, Shuko Saku, Yuko Takao, Mina Okabe, Nobutaka Iwakuma, Shigeki Shichijo, Akira Yamada, Kyogo Itoh, Yoshito Akagi

Open access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. [Research Progress of Lung Cancer Vaccines].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Uhi TohDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.ORCID https://orcid.org/0000-0002-1986-6643
Sayaka SakuraiDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Shuko SakuDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Yuko TakaoDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Mina OkabeDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Nobutaka IwakumaDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Shigeki ShichijoCancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan.ORCID https://orcid.org/0000-0003-4797-0429
Akira YamadaDivision of Cancer Vaccine, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan.ORCID https://orcid.org/0000-0003-3157-9070
Kyogo ItohCancer Vaccine Center, Kurume University School of Medicine, Kurume, Japan.
Yoshito AkagiDepartment of Surgery, Kurume University School of Medicine, Kurume, Japan.
Kurume University · JP

Funding

The Ministry of Education, Culture, Sports, Science, and Technology of Japan 26461965
6 · The paper itself

Abstract

We undertook an early phase II study of mixed 19-peptide cancer vaccine monotherapy for 14 advanced metastatic triple-negative breast cancer (mTNBC) patients refractory to systemic chemotherapy to develop a new type of cancer vaccine. The treatment protocol consisted of a weekly vaccination for 6 weeks, and there were no severe adverse events related to the vaccination throughout the trial. Increase of peptide-specific IgG against the vaccinated human leukocyte antigen-matched peptides, but not against the nonmatched peptides, was positively correlated with overall survival (OS) (P < .01). The median OS was 11.5 or 24.4 months in all 14 patients or the 10 patients who completed the vaccination. The patients with lower C-reactive protein levels or 3 or fewer systemic chemotherapies were favorable candidates for this treatment. Advancement of this therapy to the next stage of study could be warranted based on the safety and immune boosting determined herein (clinical trial registration number: UMIN000014616).

Indexed as

AdultAgedAged, 80 and overAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsCancer VaccinesDrug Resistance, NeoplasmFemaleHumansImmunization ScheduleMiddle AgedPeptidesTreatment OutcomeTriple Negative Breast NeoplasmsVaccines, SubunitAntigens, NeoplasmCancer VaccinesPeptidesVaccines, Subunitadvanced metastatic triple-negative breast cancerearly phase II trialimmunotherapymixed-peptide vaccine

Identifiers

PMID32495455
PMCPMC7419019
OpenAlexW3032192309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.